Pharmaceutical company GlaxoSmithKline will open a new research unit in China to look at traditional Chinese medicine. According to the company, Innovative TCM will be one of GSK’s R&D programs in China, aiming to transform TCM from an experience-based practice to evidence-based medicines through innovation and differentiation. “Traditional chinese medicine is a well-established system of medical practice developed through thousands of years of empirical testing and refinement of herbal mixtures, and relies generally on clinical experience,” said Zang Jingwu, senior vice president and head of R&D China.
